1 The function of inhibitory neuronal M 2 muscarinic receptors in diabetic rat lungs was investigated. 2 Neuronal M 2 muscarinic receptors inhibit acetylcholine release from parasympathetic nerves. Thus, stimulation of neuronal M 2 muscarinic receptors with muscarinic agonists, such as pilocarpine, inhibits acetylcholine release and vagally induced bronchoconstriction. In contrast, blockade of neuronal M 2 muscarinic receptors with selective M 2 muscarinic antagonists, such as AF-DX 116, potentiates acetylcholine release and vagally induced bronchoconstriction. 3 Rats were made diabetic by streptozotocin (65 mg kg 71 , i.v.). After 7 ± 14 days the rats were anaesthetized with urethane (1.5 g kg 71 , i.p.), tracheostomized, vagotomized, ventilated and paralysed with suxamethonium (30 mg kg 71 , i.v.). Some 7 day diabetic rats were treated with low doses of long acting (NPH) insulin (2 units day 71 , s.c.) for 7 days before experimentation. This dose of insulin was not sucient to restore normoglycaemia in diabetic rats. Thus, insulin-treated diabetic rats remained hyperglycaemic. 4 Distal electrical stimulation (5 ± 70 Hz, 6 s, 40 V, 0.4 ms) of the vagi caused bronchoconstriction, measured as an increase in in¯ation pressure and bradycardia. In diabetic rats, vagally induced bronchoconstriction was signi®cantly depressed vs controls. In contrast, bronchoconstriction caused by i.v. acetylcholine was similar in diabetic and control animals. 3 H]QNB (1 nM) with the agonist carbachol (10.0 nM ± 10.0 mM) from diabetic cardiac M 2 muscarinic receptors revealed a half log increase in agonist binding anity at both the high and low anity binding sites vs controls. In contrast, M 2 receptors from insulin-treated diabetic rat hearts showed no signi®cant dierence in binding anity vs controls. 8 These data show that neuronal M 2 muscarinic receptors in the lungs have increased function in diabetic rats, suggesting that insulin modulates M 2 muscarinic receptor function.